GEN Exclusives

More »

GEN News Highlights

More »
Jan 20, 2012

Merck to Pay Canadian Vioxx Claimants up to C$26.4M

  • Merck will have to shell out between C$21.8 million and C$36.9 million to settle litigation in Canada relating to its anti-inflammatory painkiller, Vioxx, which was pulled from the shelves in 2004 because of its links with heart attacks and stroke. The payment will resolve all Vioxx certified calss actions, putative class actions, and other litigation and claims relating to Vioxx in Canada. Of the total amount agreed, between C$11.3 million and C$26.4 million will be doled out to Vioxx users, with the final amount payable dependent on the number of claimants. Another C$10.5 million will cover legal costs.

    The settlement of Canadian litigation follows just two months after Merck agreed to shell out two-thirds of a previously agreed $950 million to resolve civil allegations related to Vioxx in the U.S. The final third of this total was paid as a fine relating to Merck’s plea of guilty to a misdemeanor under the Federal Food, Drug, and Cosmetic Act relating to the marketing of Vioxx as a treatment for rheumatoid arthritis before FDA had actually approved its use for this indication in 2002.

    In December 2007 Merck made an agreement with the Negotiating Plaintiffs Counsel acting on behalf of Vioxx claimants, to set aside $4.85 billion to resolve pending or existing Vioxx-related claims against the firm. By October 2007 there had been about 26,000 active Vioxx personal injury actions filed in the U.S. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »